534 results about "Enhancer" patented technology

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

The invention provides a kit and a method for detecting common fusion genes of lymphoid leukemia based on a multiple digital PCR (Polymerase Chain Reaction) method. By constructing a synergistic effect mechanism of the primer and the fluorescent probe and optimizing matching of the primer, the probe and a fluorescent marker, non-specific binding among amplification products is effectively avoided. A composite reaction aid with a specific formula, namely a PCR enhancer, is innovatively introduced, so that the amplification efficiency and specificity of a multiple detection system are remarkably improved. According to the kit provided by the invention, the integrated detection capability on seven fluorescent channels, namely Atto 425, VIC, FAM, ROX, CY5, CY5.5 and CY7, is realized in a single-hole design. By innovatively constructing an ROX + CY5 and Atto425 + VIC dual-channel joint detection system, when the ROX and CY5 channels or Atto425 and VIC channels in the same detection hole simultaneously present positive signals, two additional detection targets can be specifically interpreted. The innovative detection strategy based on channel combination enables the kit to realize precise detection of 18 fusion genes only through two detection holes in a breakthrough manner.

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

Described herein are synthetic promoters and / or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.

The invention discloses an enhancer Enh483 related to bovine muscle development and application of the enhancer Enh483 in promoting bovine myoblast proliferation and / or differentiation. According to the method, existing ATAC-Seq data and Chip-seq data in the proliferation stage and differentiation stage of buffalo myoblasts are utilized to visually analyze chromatin open areas through IGV to predict annotation enhancers, candidate enhancers Enh483 related to muscle development are screened out, and the enhancers have enhancer activity detected by a dual-luciferase vector report system; after the activity of Enh483 is inhibited, the proliferation and differentiation of buffalo myoblasts can be inhibited, which indicates that Enh483 can promote the proliferation and / or differentiation of buffalo myoblasts. According to the invention, an important theoretical basis is provided for an action mechanism of transcription regulation elements such as enhancers in muscle development, and data support is provided for buffalo breeding and strain breeding.

Polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods for expressing AAV Rep and Cap proteins are provided. In certain aspects, these polynucleotides, cells, and methods may produce higher levels of one or both of Rep and Cap transcripts. In some aspects, these polynucleotides, cells, and methods may produce higher levels of one or both of Rep and Cap proteins. In various aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods use one or more heterologous polyA sequences with one or both of the Rep and Cap coding sequences. In numerous aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may use one or more enhancers to increase expression of Rep proteins, where such enhancers can be transcriptional enhancers, translational enhancers, or combinations thereof. In certain aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may be used to produce recombinant AAV (rAAV).

The invention relates to the technical field of cancer risk prediction, in particular to a deep learning cancer risk prediction method and system based on a methylation sequence. The method comprises the following steps: acquiring DNA methylation sequencing data and reference genome annotation data in a blood sample of a cancer patient; performing functional region classification processing on the DNA methylation sequencing data according to the reference genome annotation data to obtain promoter subregion methylation data, enhancement subregion methylation data and transcription factor binding site methylation data; performing dynamic sequence similarity calculation processing on the methylation data of the promoter region to obtain a first feature vector containing importance weight of the promoter region of the cancer-related gene; the methylation sites are classified according to the functions of the methylation sites in the transcriptional regulation pathway, so that the biological interpretation of the characteristics is improved, and the synergistic effect among different functional regions can be captured.

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.

The invention discloses an Lhfpl5 gene enhancer and application thereof, and belongs to the field of gene engineering. According to the invention, the Lhfpl5 gene enhancer is found, the enhancer can obviously enhance the expression of the Lhfpl5 gene or other genes in inner ear internal and external hair cells, and the gene enhancer can be used for gene therapy of deafness by utilizing the capability of specifically enhancing the gene expression in the inner ear internal and external hair cells; the recombinant DNA containing the Lhfpl5 gene enhancer, or a carrier and other biological materials are prepared through integration, gene expression regulation and control research is carried out, and the application prospect is good.

The invention provides a method for realizing fixed-point activation of a plant genome by directionally inserting an enhancer, and particularly, by inserting a short enhancer (STE) in a specific region of a target gene promoter, a target gene can be efficiently activated, the expression level of the target gene can be enhanced by about 2000 times, and the enhancement multiple can be flexibly adjusted as required. The site-specific activation method for the plant genome has high efficiency, wide applicability and stable heredity, and has outstanding application value in plant research and breeding.

The invention belongs to the technical field of biology, and relates to a plasma marker for colorectal cancer diagnosis or prediction and application of the plasma marker. The invention creatively provides the application of specific enhancer RNA (eRNA58712) in serum in early diagnosis or detection of colorectal cancer, which marks that important progress is achieved in the aspect of finding novel biomarkers. The expression quantity of the eRNA58712 in serum of a colorectal cancer patient is obviously higher than that of a healthy individual, and the expression level of the eRNA58712 has an obvious positive correlation relationship with occurrence and development of the colorectal cancer, which means that rapid and accurate early recognition of the colorectal cancer can be realized on a molecular level by measuring the concentration of the eRNA58712 in a blood sample.

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

The invention discloses a Myo6 gene enhancer and application thereof, and belongs to the field of gene engineering. The Myo6 gene enhancer can drive the expression capacity of a reporter gene EGFP or Myo6 gene in the inner ear to be obviously enhanced, can be used for biological materials such as recombinant DNA, vectors or adenoviruses and the like, promotes the expression of the Myo6 gene or other genes in the inner ear so as to carry out gene expression regulation and control research, and is expected to be used for gene therapy of deafness.

The present invention relates to a viral gene therapy vector for removing hepatitis B viruses, a preparation method therefor, and the use thereof, aiming to solve the problem in which existing viral gene therapy vectors can only inhibit the replication of hepatitis B viruses, but cannot remove virus cccDNA. The vector comprises a promoter, an intron, an enhancer, a nuclear localization signal (NLS) functional domain encoding gene of PGLYRP2 protein, an HBV DNA binding domain encoding gene of the PGLYRP2 protein, a secretory signal peptide functional domain encoding gene of the PGLYRP2 protein, an HBV nucleocapsid-binding functional domain encoding gene of the PGLYRP2 protein, and an IRES fragment. The viral gene therapy vector can remarkably promote the removal of HBVs in the liver of mice and is used for treatment of hepatitis B virus infection.

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.

Provided are polynucleotides comprising a transcriptional control element comprising a promoter sequence having at least 80% sequence identity to SEQ ID NO: 1. SEQ ID NO:2. SEQ ID NO:3 or SEQ ID NO:4 and a cell- or tissue-specific enhancer element. Also provided are compositions (e.g., vectors, viruses, host cells, and pharmaceutical compositions) comprising said polynucleotides, methods that are useful for expressing a target gene in a host cell, and methods that are useful for expressing a target gene in a subject in need thereof.

The present disclosure provides engineered immune cells modified to overexpress tumor sensing enhancer proteins, thereby providing the engineered immune cells with an enhanced ability to migrate to and / or infiltrate tumors. In some examples, the tumor sensing enhancer proteins are tumor sensing receptors that specifically bind to non-chemokine receptors. The disclosure also provides methods including the provided engineered immune cells.

The present invention discloses an Ush1c gene enhancer and its application, belonging to the field of genetic engineering, and the nucleotide sequence of the enhancer is shown in SEQ ID No. 1. The mouse embryo microinjection system is used to confirm that the sequence is an enhancer, which can significantly enhance the transcription activity of the EGFP protein gene in the inner ear. Compared with other sequences of similar size, the enhancer sequence fragment can drive the reporter gene or Ush1c to express significantly in the inner ear, and specifically express it in inner and outer hair cells, and is suitable for recombinant DNA, vectors or adenovirus and other biological materials, and is used to promote the transcription of EGFP gene or other genes in the inner ear.

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.

The invention discloses a chicken embryo sex determination kit directly using blood as a template and application thereof. Belongs to the technical field of biology. The kit comprises Taq DNA polymerase, an upstream primer, a downstream primer and water. Compared with the prior art, the method has the beneficial effects that a PCR reaction system is optimized by adopting the super-fidelity Taq DNA polymerase, whole blood is diluted and then is directly used as a template for PCR reaction, tedious DNA extraction is not needed, meanwhile, a PCR reaction enhancer and a PCR system stabilizer are not needed to be added into the reaction system, and the operation is simple and convenient. The method has the advantages of simple and convenient operation, less time consumption, rapid identification and the like, and avoids the defects of time and labor consumption and error proneness of a traditional method.

Use of PGLYRP2 gene and a related drug thereof. The present invention relates to the field of biopharmaceuticals, and in particular, to use of the PGLYRP2 gene and the related drug thereof. The present invention aims to solve the problem that existing drugs can only inhibit the replication of hepatitis B virus and cannot eliminate viral cccDNA. The PGLYRP2 gene is used for preparing a drug for treating a hepatitis B virus infection. The PGLYRP2 gene is used for preparing a drug for eliminating hepatitis B virus cccDNA. Also provided is a gene therapy vector for eliminating hepatitis B virus. The gene therapy vector comprises a promoter, an intron, an enhancer, and a PGLYRP2 gene encoding region. The HBV virus inhibition function and the cccDNA-eliminating effect of the PGLYRP2 protein are defined, so that the elimination of HBV in liver cells and a mouse liver can be significantly promoted.

To provide a technology for enhancing the expression of RBMS3 gene.SOLUTION: Provided is a technology for enhancing the expression of RBMS3 gene with an RBMS3 gene expression enhancer containing at least one selected from the group consisting of Althaea officinalis extract, Sambucus nigra extract, Tilia cordata Mill. extract, Arnica montana extract, Alpinia zerumbet extract, Eucalyptus globulus subsp. extract, Cymbopogon citratus extract, and Origanum majorana extract.SELECTED DRAWING: Figure 1

The invention discloses an ensemble learning and deep learning-based enhancer prediction method, which comprises the following steps of: firstly, performing enhancer prediction on multi-dimensional epigenetic signal data by utilizing a Blending-KAN model so as to identify an enhancer region, and on the basis, aiming at the region which is predicted as the enhancer, segmenting the region into subsequences through a sliding window so as to obtain an enhanced region; the method comprises the following steps: firstly, constructing a plurality of sub-sequences, further predicting the probability that each sub-sequence is an enhancer through a Stacking-Auto model, and finally, accurately positioning a complete enhanced sub-region by adopting a dynamic threshold algorithm based on the probability values; according to the multi-model combination method provided by the invention, the accuracy and fine positioning capability of enhancer identification are effectively improved, and the method is expected to be applied to more complex gene regulation network researches.

In some aspects, cardiac-specific expression cassettes are provided herein. In some aspects, provided herein is an expression cassette comprising a polynucleotide sequence encoding a gene product for therapy of a heart disease, wherein the polynucleotide sequence is operably linked to promoter (e.g., a cardiac-specific promoter), and optionally an enhancer (e.g., a cardiac-specific enhancer). In some aspects, the disclosure provides recombinant adeno-associated virus (rAAV) virions, comprising a capsid protein and a viral genome comprising an expression cassette comprising a polynucleotide sequence encoding a therapeutic gene product, e.g., dwarf open reading frame (DWORF) polypeptide, operably linked to a promoter, the expression cassette flanked by inverted terminal repeats. The disclosure further provides pharmaceutical compositions and methods of treating or preventing heart disease.

The present invention relates to engineered liver-specific core promoters, synthetic promoters (which contains the engineered core promoters and enhancers), expression vectors (which contains the synthetic promoter), as well as methods of using the promoter or the expression vector thereof to address the need in the field, including treatment of various genetic diseases or conditions associated with the liver. In some embodiments, the liver-specific promoter includes continuous or discontinuous genome sequences from SERPINA1 genome.

The invention relates to a FAP-targeted CAR-macrophage with an enhanced intercellular effect as well as a preparation method and application of the FAP-targeted CAR-macrophage. The CAR-macrophage contains a FAP specific CAR for targeting fibrosis and a burial effect enhancer Lgmn, the amino acid sequence of the FAP specific CAR for targeting fibrosis is as shown in SEQ ID NO. 1, and the nucleotide sequence of the FAP specific CAR for targeting fibrosis is as shown in SEQ ID NO. 2; the amino acid sequence of the cell burial effect enhancer is as shown in SEQ ID NO.3, and the nucleotide sequence of the cell burial effect enhancer is as shown in SEQ ID NO.4. The CAR-macrophage can specifically target an FAP target spot, can also enhance a cellular burial effect signal channel, realizes combination of CAR-macrophage therapy and intracellular degradation capability improvement, enhances intracellular rapid degradation and removal of phagocytized activated fibroblasts by expressing Lgmn protein, exerts and amplifies the phagocytic effect of the CAR-macrophage on the activated fibroblasts, and improves the activity of the CAR-macrophage on the activated fibroblasts. Therefore, an efficient anti-fibrosis effect is obtained.

An engineered extracellular vesicle (EV) for delivering a bioactive cargo, the engineered EV comprising an endosomal escape enhancer and a cargo. Plasmids, polynucleotide sequences, cells, methods of making and analysis, pharmaceutical compositions and uses thereof.

The invention provides a kit for detecting human BRAF gene V600E and TERT gene promoter mutation, and belongs to the technical field of biology. The kit comprises a primer, a probe, a 5 * PCR (Polymerase Chain Reaction)-Enhancer, a 10 * PCR Buffer, dNTP (Deoxyribonucleoside Triphosphate) Mix, MalTaq DNAPlyase, magnesium ions, DEPC (Diethylpyrocarbonate) water, a positive control and a negative control. According to the present invention, the ARMS-PCR detection technology is adopted to detect the specific gene mutation, and the target mutation site is identified by designing the specific primer and the probe, such that the detection specificity and the detection sensitivity are improved; by combining with a Taqman probe technology, the fluorescent signal change in the PCR amplification process can be monitored in real time, so that whether mutation of a BRAF V600E site, a TERT C228T site and a TERT C250T site exists or not is accurately judged; according to the method, pre-amplification of 15 cycles is adopted, then quantitative amplification of 30 cycles is adopted, and when the initial amount of the target DNA is very low, the copy number of the target DNA can be increased, so that the detection accuracy and sensitivity are further improved.

The present invention discloses a Mitf gene enhancer and its application in improving the gene-specific expression of cochlear stria vascular cells, and relates to the field of gene expression and regulation technology. The nucleotide sequence of the enhancer is shown in SEQ ID No. 1. The mouse embryo microinjection system was used to confirm that the sequence is an enhancer, which can significantly enhance the transcription activity of the EGFP protein gene in the cochlear stria vascular cells. Compared with other sequences of similar size, the enhancer sequence fragment can drive the reporter gene or Mitf to be specifically expressed in the cochlear stria vascular cells and the expression level is significantly enhanced. The enhancer is suitable for biological materials such as recombinant DNA, vectors or adenoviruses, and is used to promote the transcription of the EGFP gene or other genes in the cochlear stria vascular cells.

Described herein are synthetic promoters and / or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.